Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Egeberg

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
The British Journal of Dermatology|August 19, 2016
Predictors of drug survival for tumour necrosis factor-α and interleukin 12/23 antagonists in psoriasisA Egeberg
The British Journal of Dermatology|December 29, 2015
Does systemic antipsoriatic therapy affect the cardiovascular risk?A Egeberg
The British Journal of Dermatology|October 21, 2017
Getting tired of psoriasis?A Egeberg
The British Journal of Dermatology|March 1, 2017
Evidence-based management of rosaceaA Egeberg
The British Journal of Dermatology|October 16, 2018
The good, the bad and the malignantA Egeberg
The British Journal of Dermatology|October 21, 2017
Cardiometabolic disease in atopic dermatitis: the heart of the matterA Egeberg
The British Journal of Dermatology|April 27, 2019
Chronic urticaria - bad to the bone?A Egeberg
The British Journal of Dermatology|October 30, 2016
Fumarates for treatment of psoriasisA Egeberg
The British Journal of Dermatology|July 22, 2017
A critical eye on registry data in psoriasisA Egeberg, A Nast
The British Journal of Dermatology|May 9, 2018
Drug survival of secukinumab for moderate-to-severe plaque psoriasis: reply from authorsA Egeberg, L Skov
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
The British Journal of Dermatology|August 19, 2016
Predictors of drug survival for tumour necrosis factor-α and interleukin 12/23 antagonists in psoriasisA Egeberg
The British Journal of Dermatology|December 29, 2015
Does systemic antipsoriatic therapy affect the cardiovascular risk?A Egeberg
The British Journal of Dermatology|October 21, 2017
Getting tired of psoriasis?A Egeberg
The British Journal of Dermatology|March 1, 2017
Evidence-based management of rosaceaA Egeberg
The British Journal of Dermatology|October 16, 2018
The good, the bad and the malignantA Egeberg
The British Journal of Dermatology|October 21, 2017
Cardiometabolic disease in atopic dermatitis: the heart of the matterA Egeberg
The British Journal of Dermatology|April 27, 2019
Chronic urticaria - bad to the bone?A Egeberg
The British Journal of Dermatology|October 30, 2016
Fumarates for treatment of psoriasisA Egeberg
The British Journal of Dermatology|July 22, 2017
A critical eye on registry data in psoriasisA Egeberg, A Nast
The British Journal of Dermatology|May 9, 2018
Drug survival of secukinumab for moderate-to-severe plaque psoriasis: reply from authorsA Egeberg, L Skov
Pageof 11